UCB

Bimzelx (bimekizumab) is a dual IL-17A and IL-17F inhibitor from UCB that neutralises two closely related cytokines driving inflammation in skin, joints, and spine. It treats moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and hidradenitis suppurativa in adults.

Bimekizumab is an injection that blocks two inflammatory proteins called IL-17A and IL-17F. These proteins are released by overactive immune cells and

Cimzia (certolizumab pegol) is a PEGylated antibody fragment from UCB that neutralises TNF-alpha. Without the Fc portion, it is designed to calm inflammation in rheumatoid arthritis and Crohn disease while behaving differently from full-length antibodies.

TNF-alpha is one of the main chemical messengers that keep inflammation going in rheumatoid arthritis and Crohn disease. Certolizumab pegol is an anti